EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Elevation of S2 ‐bound α1‐acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma

Carlos Oltmanns iD, Birgit Bremer, Laura Kusche, Per Stål, Robin Zenlander, Jan Tauwaldt, Ingvar Rydén, Peter Påhlsson, Markus Cornberg iD, Heiner Wedemeyer

Journal of Viral Hepatitis · 2024

DOI: 10.1111/jvh.13943 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von Carlos Oltmanns und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany. Hauptthemen laut MEDLINE: Biomarkers, Carcinoma, Hepatocellular, Hepatitis C, Chronic, Liver Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Glycobond AB, Swedish Cancer Society, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is an urgent need for new high‐quality markers for the early detection of hepatocellular carcinoma (HCC). Åström et al. suggested that S2‐bound α1‐acid glycoprotein (AGP) might be a promising marker. Consequently, we evaluated the predictive advantage of S2‐bound AGP in the early detection of HCC. In a retrospective case–control study of patients chronically infected with hepatitis C virus (HCV) and treated with direct‐acting antiviral agents ( n = 93), we measured S2‐bound AGP using the HepaCheC® ELISA kit (Glycobond AB, Linköping, SE) at the start of treatment, end of treatment and follow‐up (maximum: 78 months). Patients were retrospectively propensity score matched (1:2). Thirty‐one patients chronically infected with HCV developed HCC after a sustained virological response, while 62 did not. In addition, samples of patients with chronic hepatitis B virus infection, metabolic dysfunction‐associated steatotic liver disease and HCC of different etiologies were analysed. S2‐bound AGP elevation in HCC patients was confirmed. However, we did not observe a predictive advantage of S2‐bound AGP for the early detection of HCC during treatment and follow‐up. Interestingly, S2‐bound AGP levels correlated with aspartate aminotransferase (ρ = .56, p = 9.5×10 −15 ) and liver elastography (ρ = .67, p = 2.2×10 −16 ). Of note, S2‐bound AGP decreased in patients chronically infected with HCV after treatment‐induced HCV clearance. Fucosylated S2‐bound AGP levels were elevated in patients with chronic HCV and HCC. The potential role of S2‐bound AGP as a novel tumour marker requires further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersCarcinoma, HepatocellularHepatitis C, ChronicLiver NeoplasmsOrosomucoidAdultAgedFemaleHumansMaleMiddle AgedAntiviral AgentsBiomarkers, TumorCase-Control StudiesEarly Detection of CancerHepacivirusRetrospective Studies

Stichwörter der Autor:innen

ASTHBVHCCHCVMASLDS2‐bound AGPbiomarkercancerelastographysurveillance

Substanzen

Antiviral AgentsBiomarkersBiomarkers, TumorOrosomucoid

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
  • Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH), Hannover, Germany.
  • Cluster of Excellence Resolving Infection Susceptibility (RESIST; EXC 2155), Hannover Medical School, Hannover, Germany.
  • TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Department of Medicine, Karolinska Institutet, Huddinge, Sweden.
  • Division of Hepatology, Department of Upper GI Diseases, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Carlos Oltmanns, Markus Cornberg

Förderung

  • Glycobond AB
  • Swedish Cancer Society
  • Deutsche Forschungsgemeinschaft
  • Else Kröner-Fresenius-Stiftung
  • Cancerfonden

Zitieren

APA

Oltmanns, C., Bremer, B., Kusche, L., Stål, P., Zenlander, R., Tauwaldt, J., Rydén, I., Påhlsson, P., Cornberg, M., & Wedemeyer, H. (2024). Elevation of S2 ‐bound α1‐acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13943

Vancouver

Oltmanns C, Bremer B, Kusche L, Stål P, Zenlander R, Tauwaldt J, et al. Elevation of S2 ‐bound α1‐acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.13943

BibTeX
@article{Oltmanns2024,
  author = {Oltmanns, Carlos and Bremer, Birgit and Kusche, Laura and Stål, Per and Zenlander, Robin and Tauwaldt, Jan and Rydén, Ingvar and Påhlsson, Peter and Cornberg, Markus and Wedemeyer, Heiner},
  title = {Elevation of S2 ‐bound α1‐acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma},
  journal = {Journal of Viral Hepatitis},
  year = {2024},
  doi = {10.1111/jvh.13943}
}
Kostenlos starten →